Phd in ENDOCRINOLOGICAL SCIENCES

Research: Clinical parameters and novel serum biomarkers as surrogates of hepatic and extrahepatic impairment in patients with obesity and diabetes mellitus affected by Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Nutrition Biologist Clinical research on obesity, type 1 and type 2 diabetes mellitus, insulin resistance, inflammation, and oxidative stress, with a focus on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and liver fibrosis. WORK EXPERIENCE: - November 2023: PhD in Endocrinological Sciences, Department of Experimental Medicine - Sapienza University of Rome (in progress). EDUCATION AND TRAINING: - 2022-2023 Post-graduate Master in Dietetics and Clinical Nutrition (Istituto Alta Formazione, IAF, Rome) - 2020-2022 Master's Degree in Food Sciences and Human Nutrition (LM-61), Class of degree in Sciences of Nutrition Human (LM-61), University of Perugia, Department of Pharmaceutical Sciences. Degree grade: 110/110 cum laude with academic distinction Thesis title: Metabolic resistance in obesity: focus on the FGF21-PPARGAMMA-ADIPONECTIN axis Supervisor: Professor Michela Codini -2016-2019 Bachelor's Degree in Food and Gastronomy Sciences (L-26), San Raffaele University, Rome (Uniroma 5) Degree grade: 110/110 cum laude Thesis title: Fake Food: the business of anonymity Supervisor: Professor Alex Revelli Sorini Co- Supervisor: Professor Susanna Cutini -2008-2013 High School Diploma in Science, Chemical-Biological Adress-Levi Montalcini, Liceo Scientifico Ettore Majorana, Latina Grade: 95/100 PROFESSIONAL QUALIFICATIONS, CERTIFICATIONS: Professional Qualifications - State Examination first Session 2022 with the achievement of the Qualification to practice as a Biologist – University of Bari Grade: 10/10 - Registration with the Order of Biologists of Lazio and Abruzzo, 2023, Section A, No. 100018 Certifications - Good Clinical Practice (ICH-GCP E6(R3)), 2025 - Use of FibroScan 530 (Transient Elastography), 2024 - Good Clinical Practice (ICH-GCP E6(R2)), 2024 CLINICAL TRIAL: -Synchronize Trial¨- A Phase 3, randomised, double-blind, parallel-group, event driven, cardiovascular safety study with survodutide administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight related complications or risk factors for CVD Role: Sub Investigator CONFERENCE ABSTRACT PRESENTATION: - “Weight Loss Effectiveness of Semaglutide in Real-World Obesity Management: Analysis by Liraglutide Switch, Sex, and Baseline BMI.” 33rd European Congress on Obesity - ECO 2026 - May 12-15, 2026 - “Real-world effectiveness and safety of semaglutide in obesity: early effects on weight loss and metabolic parameters.” 33rd European Congress on Obesity - ECO 2026 - May 12-15, 2026 - “Metabolic-associated fatty liver disease (MASLD): a growing comorbidity in type 1 diabetes.” Joint AMD-SID Lazio Congress- Diabetes Disease in 2025: Tradition, Innovation, and New Frontiers- October 24-25, 2025 - Rome - "Diabetes and Obesity: The Renal Effects of GLP-1 Analogs" - SID-AMD Lazio Regional Congress - November 29-30, 2024 - Rome - "Effects of Glucagon-like Peptide-1 Receptor Agonists on the Liver in Patients with Obesity and Type 2 Diabetes" - SID National Congress - October 23-26, 2024 - Rimini - "Gender Difference in Response to Treatment with Liraglutide 3.0 mg" - 31st European Congress on Obesity - ECO 2024 - May 12-15, 2024 EDITORIAL ACTIVITY: - Member of the editorial board of the Italian Society of Diabetes (SID) PARTICIPATION IN RESEARCH PROJECTS: - “Comparative effects of non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) on risk of extra-hepatic complications”, PRIN: RESEARCH PROJECTS OF RELEVANT NATIONAL INTEREST - 2022 PNRR call; - “Effect of weight loss obtained with semaglutide or sleeve gastrectomy on renal function in obese patients”, Ateneo Medio Project 2023. CONTRIBUTIONS TO SCIENTIFIC JOURNALS: - "Is bariatric surgery still a first-line option for the treatment of obesity?" - Il Diabete Online, Official Journal of the Italian Society of Diabetology (Obesity Updates, Vol. 37, No. 3, October 2025) - DOI: https://doi.org/10.30682/ildia2503e - “An Unusual Type of Diabetes: “Not-1” and “Not-2”” - Il Diabete Online, Official Journal of the Italian Society of Diabetology (Clinical Update, Vol. 36, No. 3, October 2024) - DOI: https://doi.org/10.30682//ildia2403g